The shares in MEIP are selling for over 20 times what Novogen are worth when you consider that each NVGN share is 25 NRT (Novogen) shares, and rightly so, MEIP is further advanced along the testing path, but there is one glaring difference between these companies, MEIP have about 5 compounds for which they own the IP to, Novogen at the moment has one compound they are looking at CS-6 which is highly active against ovarian cancer stem cells.
But one huge difference between both companies is that Novogen own the technology platform that they are working with, not just the compound or compounds as in MEIP's case.
The Novogen technology platform has the potential to revolutionise the development of small molecules as drugs for a wide range of human diseases, with cancer a particular focus.
So cancer is the focus at the moment, but not just with CS-6, there is also another compound/s on the way called CS-6XX
Novogen are working on a platform technology The CS-6XX program is generating libraries of molecules that will be developed as potential dual therapy super benzopyrans. The dual therapy development strategy comprises testing the new super benzopyrans in concert with standard of care chemotherapeutic agents.